Cogprints

The role of statin drugs in combating cardiovascular diseases –A review

Suresh Pichandi , Palanisamy Pasupathi, Y.Yagneswara Rao, Jawahar Farook, Athimoolam Ambika, Babu Shankar Ponnusha , Sathiyamoorthy Subramaniyam, Rajaram Virumandy, Boopathi subramaniyam Int J Cur Sci Res. (2011) The role of statin drugs in combating cardiovascular diseases –A review. [Journal (Paginated)]

Full text available as:

[img]
Preview
 PDF (The role of statin drugs in combating cardiovascular diseases –A review)
Available under License Creative Commons Attribution No Derivatives.
1112Kb

Abstract

Statins clearly confer substantial benefit in people with established cardiovascular (CV) disease. Increased cholesterol levels have been associated with cardiovascular diseases (CVD), and statins are therefore used in the prevention of these diseases. Studies have found that the ability of a particular statin to lower or reduce LDL is proportional to the amount it can increase HDL levels. This review article will focus on the effective role of statin in cardiovascular disease and comparison was made between various classes of statin drugs.

Item Type:Journal (Paginated)
Keywords:Cardiovascular disease, Hyperlipidaemic patients, statin drugs.
Subjects:JOURNALS
ID Code:7309
Deposited By: CurrentSciDirect Publications, International Journal of Current Scientific Research (IJCSR)
Deposited On:02 May 2011 15:53
Last Modified:02 May 2011 15:53

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

[1] Paulweber B.Statins in primary prevention of coronary heart disease. Wien Med Wochenschr. 1999;149:129-138.

[2] Vasa M, Fichtlscherer S, Adler K. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001; 103:2885-2890.

[3] Shepherd J, Cobbe SM, Ford I. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.

[4] Christie M,Ballantyne. There are currently six statins available—simvastatin, lovastatin, pravastatin,

atorva- statin, fluvastatin, and rosuvastatin—all of which lower LDL cholesterol, These have each been used widely in recipients of solid organ.2009;5:450-584.

[5] Vaughn CJ, Delanty N. Neuroprotective actions of statins in cerebral ischemia and stroke. Stroke. 1999; 30:1969-1973.

[6] Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002; 4:34-41.

[7] Durazzo AES, Machado FS, Ikeoka D, Peuch-Leao P, Caramelli B. Effect of atorvastatin on cardiovascular events after vascular surgery. Circulation. 2002; 106:339-343.

[8] Ballantyne CM. Statins after cardiac transplantation: which statin, what dose, and how low should we go? J Heart Lung Transplant. 2000; 19:515–517.

[9]Kobashigawa J, Katznelson S, Laks H. Effect of pravastatin in outcomes after cardiac transplantation. N Engl J Med. 1995; 333:621–627.

[10]Wenke K, Meiser B, Thiery J. Simvastatin reduces graft vessel disease and mortality after heart transplantation—a four year randomised trial. Circulation. 1997; 96:1398–1402.

[11]Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990; 343:425–430.

[12] Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000; 10:143–148.

[13] Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron. 1994;68:57–62.

[14] Raithatha N, Smith Richard D. Paying for statins. BMJ. 2004; 328:400–402.

[15] Jialal I, Stein D, Balis D. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933–1935.

[16] Pedersen TR, Faergeman O, Kastelein JP, Olsson AG, Tikkanen MJ, Holme I. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA. 2005;294:2437–2445.

[17] Nawrocki JW,Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.Arterioscler Thromb Vasc Biol.1995;15 :678–682.

[18] Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.2004; 364:685-696.

[19]Tonelli M, Moyé L, Sacks FM. Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98-104.

[20] Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 ;326:1423–1423.

[21] Wei L, Ebrahim S, Bartlett C, Davey P D, Sullivan F M, MacDonald T M. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ. 2005 ;330:821–822.

[22] Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999 ;341:498–511.

[23] Creese A. Global trends in health care reform. World Health Forum. 1994;15(4):317–322.

[24] Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care. 1993 ;9:26–36.

[25] Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 ;333:1301–1307.

[26] D'Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001 ;286:180–187.

[27] McKenney JM, Kinosian B. Economic benefits of aggressive lipid lowering: a managed care perspective. Am J Manag Care. 1998 ;4:65–74.

[28] Spearman ME, Summers K, Moore V, Jacqmin R, Smith G, Groshen S. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. Clin Ther. 1997;19:582–539.

[29] LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999 ;282:2340–2346.

[30] Field K, Thorogood M, Silagy C, Normand C, O'Neill C, Muir J. Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ. 1995 ;310:1109–1112.

[31] Assmann G, Schulte H. Primary prevention of coronary heart disease in the Federal Republic of Germany. Analysis of cost-effectiveness. Drugs. 1990;40 :1:33–37.

[32] Schulman KA, Kinosian B, Jacobson TA, Glick H, Willian MK, Koffer H, Eisenberg JM. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA. 1990 ;264:3025–3033.

[33] Perreault S, Levinton C, Le Lorier J. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol. 2000 ;7:144–154.

[34] Spearman ME, Summers K, Moore V, Jacqmin R, Smith G, Groshen S. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. Clin Ther. 1997;19:582–539.

[35] Cucherat M, Boissel JP. A mathematical model for the determination of the optimum value of the treatment threshold for a continuous risk factor. Eur J Epidemiol. 1998 Jan;14(1):23–29.

[36] Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. 1997 ;6:589–601.

[37] Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.2006;9:565-581.

[38]Lim SS, Vos T, Peeters A, Liew D, McNeil JJ. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust. 2001 ;175:459–464.

[39] Kendrick J,Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study.

[40]Dotani MI, Elnicki DM, Jain AC,Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol .2000; 86:1128-1130.

[41] Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA.2006;13:1556–65.

Metadata

Repository Staff Only: item control page

Cogprints is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.